Recombinant Human Papillomavirus Nonavalent Vaccine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
AIDS-Related Human Papillomavirus Infection
Conditions
AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection
Trial Timeline
Jul 31, 2019 → Aug 5, 2025
NCT ID
NCT03284866About Recombinant Human Papillomavirus Nonavalent Vaccine
Recombinant Human Papillomavirus Nonavalent Vaccine is a phase 3 stage product being developed by Merck for AIDS-Related Human Papillomavirus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03284866. Target conditions include AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection.
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03284866 | Phase 3 | Completed |
Competing Products
1 competing product in AIDS-Related Human Papillomavirus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selumetinib | AstraZeneca | Phase 1/2 | 24 |